Product image of Ibandronic Acid Synthon (Ibandronic Acid) supplied by GNH India

Ibandronic Acid Synthon

Active Ingredient:
Ibandronic Acid
Origin:
EU

Ibandronic Acid Synthon (Ibandronic Acid)

Ibandronic Acid, the active ingredient in Ibandronic Acid Synthon, is a bisphosphonate presented as a strength/form for oral use. It treats osteoporosis in post‑menopausal women, men at risk of fracture, and patients receiving long‑term glucocorticoid therapy.
GNH India supplies Ibandronic Acid Synthon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Synthon Bv

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Ibandronic Acid is a bisphosphonate indicated for conditions involving reduced bone density.

  • Osteoporosis: lowers the risk of vertebral and hip fractures by increasing bone mineral density.
  • Male osteoporosis: improves bone strength and reduces fracture incidence in men with low bone mass.
  • Glucocorticoid‑induced osteoporosis: helps maintain bone density in patients receiving chronic steroid therapy.

How It Works

  • Ibandronic Acid binds selectively to hydroxyapatite crystals at sites of active bone remodeling. When osteoclasts attempt to resorb bone, the drug is internalized, inhibiting the mevalonate pathway and preventing prenylation of small GTP‑binding proteins, which leads to reduced osteoclast activity and decreased bone resorption.

Side Effects

Ibandronic Acid may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Gastrointestinal discomfort: nausea, abdominal pain, dyspepsia.
  • Musculoskeletal pain: bone, joint or muscle aches.
  • Headache.
  • Transient flu‑like symptoms after the first dose.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw.
  • Atypical femur fracture.
  • Severe esophagitis or esophageal ulceration.
  • Acute‑phase reaction with fever and myalgia.
  • Renal impairment, especially in patients with pre‑existing kidney disease.
  • Hypersensitivity reactions including rash or anaphylaxis.

Precautions & Warnings

Before initiating therapy, clinicians should assess patient risk factors and monitor for specific concerns.

  • Renal function: evaluate creatinine clearance and avoid use in severe renal impairment.
  • Gastro‑esophageal disease: ensure no active ulcer or severe reflux before prescribing.
  • Calcium/Vitamin D status: correct deficiencies to support bone health.
  • Concomitant medications: review drugs that may irritate the esophagus or affect renal function.
  • Patient education: advise taking the tablet with a full glass of water on an empty stomach and remaining upright for at least 30 minutes.

Store at room temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Ibandronic Acid can interact with several medicines, requiring careful management.

Major Interactions (Avoid)

  • Other bisphosphonates or bone‑active agents: may increase risk of oversuppression of bone turnover.
  • Calcium, magnesium, aluminum, or iron supplements taken within 30 minutes: markedly reduce absorption.
  • Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs in high doses): exacerbate renal toxicity.

Moderate Interactions (Monitor Closely)

  • Proton‑pump inhibitors: may affect gastric pH and drug dissolution.
  • Oral corticosteroids: increase risk of gastrointestinal irritation.
  • Anticoagulants such as warfarin: monitor INR for potential changes.
  • Diuretics: watch for electrolyte disturbances that could affect bone metabolism.

Frequently Asked Questions

Ibandronic Acid Synthon contains the bisphosphonate Ibandronic Acid and is used to treat osteoporosis. It helps increase bone mineral density and reduces the risk of fractures in patients with low bone mass, including post‑menopausal women, men, and individuals on long‑term glucocorticoid therapy.

The drug binds to hydroxyapatite at active bone remodeling sites. When osteoclasts attempt to resorb bone, Ibandronic Acid is taken up and blocks the mevalonate pathway, preventing prenylation of essential proteins. This inhibition reduces osteoclast activity, leading to decreased bone resorption and stronger bone.

The specific dosing regimen for Ibandronic Acid Synthon is determined by the prescribing clinician based on the patient’s condition, renal function, and other factors. Healthcare professionals set the dose and frequency according to approved guidelines and individual patient needs.

Safety data for Ibandronic Acid in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ibandronic Acid is a potent bisphosphonate that offers monthly or quarterly dosing options, which can improve adherence compared with daily or weekly agents. Compared with other bisphosphonates like alendronate, it has a similar efficacy in fracture risk reduction but may have a different side‑effect profile, especially regarding gastrointestinal tolerance.

Ibandronic Acid Synthon should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product away from excessive heat and humidity to maintain stability.

The medication is taken orally, usually as a tablet. Patients should swallow the tablet with a full glass of water on an empty stomach, at least 30 minutes before any food, drink, or other medication, and remain upright for the same period to reduce the risk of esophageal irritation.

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe esophagitis or ulceration, acute‑phase reactions with fever and muscle pain, and potential renal impairment. Patients should be monitored for these events, and any signs such as persistent jaw pain or unusual thigh pain should prompt immediate medical evaluation.

Ibandronic Acid is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min), active esophageal disorders, hypersensitivity to the drug, or those who cannot remain upright after dosing. It should also be avoided in individuals with known allergy to bisphosphonates.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ibandronic Acid

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT